Pharmacologic: estrogen receptor antagonists
Treatment of hormone receptor–positive metastatic breast cancer in postmenopausal women with progressive disease that has not responded to antiestrogen therapy.
Competitively binds to estrogen receptors. Binding results in down-regulation of estrogen receptor protein in cancerous breast tissue. Therapeutic Effects: Decreased progression of hormone receptor-positive breast cancer.
Adverse Reactions/Side Effects
CNS: headache, weakness, anxiety, depression, dizziness, insomnia. EENT: pharyngitis. Resp: dyspnea, increased cough. CV: vasodilation (hot flushes), chest pain, edema. GI: abdominal pain, constipation, diarrhea, nausea, vomiting, anorexia. GU: pelvic pain, urinary tract infection. Derm: rash, sweating. Local: pain/inflammation at injection site. Hemat: anemia. MS: back pain, bone pain, arthritis. Neuro: paresthesia. Misc: fever, flu syndrome.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
Monitor signs of anemia, including unusual weakness, fatigue, shortness of breath with exertion, and bruising. Notify physician if these signs occur.
Assess peripheral edema using girth measurements, volume displacement, and measurement of pitting edema (See Appendix N). Report increased swelling in feet and ankles or a sudden increase in body weight due to fluid retention.
Monitor any chest pain or difficult, labored breathing. Attempt to differentiate whether symptoms are drug induced or caused by cardiovascular dysfunction (e.g., angina that occurs during exercise).
Assess any back pain, bone pain, pelvic pain, or other musculoskeletal pain. Suggest additional tests (radiography, MRI) as needed to rule out fracture.
Monitor and report depression, anxiety, or other changes in mood and behavior.
Assess signs of paresthesia (numbness, tingling) or muscle twitching. Perform objective tests, including electroneuromyography and sensory testing to document any drug-related neuropathic changes.
Monitor IM injection site for pain, swelling, and irritation. Report prolonged or excessive injection-site reactions to the physician.
Instruct patient to report other troublesome side effects such as severe or prolonged headache, sleep loss, cough, throat irritation, hot flashes, flu-like symptoms, urinary tract infection, skin reactions (rash, sweating), or GI problems (nausea, diarrhea, vomiting, constipation, abdominal pain, loss of appetite).
Absorption: Well absorbed following IM administration.
Distribution: Rapidly and extensively distributed.
Metabolism and Excretion: Mostly metabolized by the liver; negligible renal elimination.
Log In to View More
If your institution is currently a subscriber
of the F.A. Davis PT Collection please sign in below.
If your institution is not a subscriber
please click here
to learn more.
Want remote access to your institution's subscription?
Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.
If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.